18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

@article{Schonhaut201718FT,
  title={18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.},
  author={Daniel R. Schonhaut and Corey T McMillan and Salvatore Spina and Bradford C. Dickerson and Andrew D. Siderowf and Michael D. Devous and Richard M. Tsai and Joseph R. Winer and David Stark Russell and Irene Litvan and Erik D Roberson and William W. Seeley and Lea Tenenholz Grinberg and Joel H. Kramer and Bruce L. Miller and Peter S Pressman and Ilya Nasrallah and Suzanne L. Baker and Stephen N. Gomperts and Keith A. Johnson and Murray Grossman and William J. Jagust and Adam L. Boxer and Gil D. Rabinovici},
  journal={Annals of neurology},
  year={2017},
  volume={82 4},
  pages={
          622-634
        }
}
OBJECTIVE 18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in Alzheimer disease, but tissue studies assessing binding to tau aggregates in progressive supranuclear palsy (PSP) have yielded mixed results. We compared in vivo 18 F-flortaucipir uptake in patients meeting clinical research criteria for PSP (n = 33) to normal controls (n = 46) and patients meeting criteria for Parkinson disease (PD; n = 26). METHODS Participants underwent magnetic resonance… CONTINUE READING
Highly Cited
This paper has 143 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS